CAlgary SAlt for POTS
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorUniversity of Calgary
About this trial
Many patients with postural orthostatic tachycardia syndrome (POTS) have decreased plasma volume. Current POTS guidelines recommend \~10 g of salt and 2-3 L of fluid per day. Despite this recommendation, there is no long term data evaluating the use of salt in POTS. This randomized, placebo-controlled cross-over trial will evaluate a high salt diet, compared to a normal salt diet over a period of 3 months. Participants will complete 3 in lab evaluations including autonomic function testing, tilt table testing, blood volume and urine sodium evaluation, plasma catecholamine measurements and and cytokine measurements.
Eligibility criteria
Qualifiers
Sustained, excessive orthostatic tachycardia ≥ 30 bpm within 10 minutes standing.
Absence of orthostatic hypotension (>20/10 mmHg decrease) within 3 minutes standing.
Chronic orthostatic symptoms that improve with recumbence.
Age 18-60 years old.
Disqualifiers
Overt cause for postural tachycardia (i.e., acute dehydration, thyroid disease)
Participants with somatization or severe anxiety symptoms will be excluded
Pregnant (self-reported)
Underlying causes of tachycardia including acute hypovolemia, endocrinopathy, anemia, anxiety, medication effects, recreational drug effects, and prolonged bedrest.
Trial design
Treatments tested in this trial
- Sodium Chloride Capsules
- Microcystalline Cellulose Capsules
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov